KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $3.1 billion.

  • Bristol Myers Squibb's Net Cash Flow rose 10519.74% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 billion, marking a year-over-year increase of 318691.98%. This contributed to the annual value of -$1.0 billion for FY2024, which is 14816.19% down from last year.
  • According to the latest figures from Q3 2025, Bristol Myers Squibb's Net Cash Flow is $3.1 billion, which was up 10519.74% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Bristol Myers Squibb's Net Cash Flow registered a high of $3.9 billion during Q4 2023, and its lowest value of -$3.6 billion during Q1 2021.
  • Its 5-year average for Net Cash Flow is $41.6 million, with a median of $58.0 million in 2021.
  • As far as peak fluctuations go, Bristol Myers Squibb's Net Cash Flow surged by 57091.93% in 2021, and later crashed by 276896.55% in 2022.
  • Bristol Myers Squibb's Net Cash Flow (Quarter) stood at $491.0 million in 2021, then surged by 159.27% to $1.3 billion in 2022, then surged by 204.24% to $3.9 billion in 2023, then crashed by 32.84% to $2.6 billion in 2024, then rose by 19.92% to $3.1 billion in 2025.
  • Its Net Cash Flow stands at $3.1 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $462.0 million for Q1 2025.